Cargando…
Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
BACKGROUND: Pleuroparenchymal fibroelastosis (PPFE) has a variable disease course with dismal prognosis in the majority of patients with no validated drug therapy. This study is to evaluate the effect of nintedanib in patients with idiopathic and secondary PPFE. Patients admitted to a tertiary care...
Autores principales: | Nasser, Mouhamad, Si-Mohamed, Salim, Turquier, Ségolène, Traclet, Julie, Ahmad, Kaïs, Philit, François, Bonniaud, Philippe, Chalabreysse, Lara, Thivolet-Béjui, Françoise, Cottin, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501734/ https://www.ncbi.nlm.nih.gov/pubmed/34627338 http://dx.doi.org/10.1186/s13023-021-02043-5 |
Ejemplares similares
-
Idiopathic Pleuroparenchymal Fibroelastosis
por: Bonifazi, Martina, et al.
Publicado: (2017) -
Idiopathic Pleuroparenchymal Fibroelastosis
por: Tavakolian, Kameron, et al.
Publicado: (2022) -
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
por: Nasser, Mouhamad, et al.
Publicado: (2021) -
Role of alveolar collapse in idiopathic pleuroparenchymal fibroelastosis
por: Kinoshita, Yoshiaki, et al.
Publicado: (2020) -
Remodeling of the pulmonary artery in idiopathic pleuroparenchymal fibroelastosis
por: Kinoshita, Yoshiaki, et al.
Publicado: (2020)